Neurotoxicity of cancer chemotherapy

Seminars in Neurology

Volumn 30, Issue 3, 2010, Pages 273-286

  Dropcho, Edward J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Chemotherapy adverse effects; polyneuropathy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ASPARAGINASE; BEVACIZUMAB; BORTEZOMIB; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLONAZEPAM; CYTARABINE; DEXAMETHASONE; DOCETAXEL; EPOTHILONE DERIVATIVE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PHENYTOIN; PROCARBAZINE; SURAMIN; THALIDOMIDE; UNINDEXED DRUG;

ACUTE BRAIN DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; AMNESIA; ANXIETY DISORDER; ASEPTIC MENINGITIS; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; BRACHIAL PLEXUS INJURY; BRAIN DISEASE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; CEREBRAL BLINDNESS; CHOREOATHETOSIS; CLINICAL FEATURE; COLON CARCINOMA; CONFUSION; DELIRIUM; DEPRESSION; DISORIENTATION; DYSARTHRIA; DYSESTHESIA; FEVER; GAIT DISORDER; GLIOBLASTOMA; HEADACHE; HUMAN; IRRITABILITY; LETHARGY; LEUKEMIA; LEUKEMIC MENINGITIS; LEUKOENCEPHALOPATHY; LYMPHOMA; MENTAL DISEASE; MUSCLE RIGIDITY; MYOCLONUS; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; POLYNEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SARCOMA; SEIZURE; SENSORIMOTOR POLYNEUROPATHY; SENSORY POLYNEUROPATHY; SIDE EFFECT; SOMNOLENCE; SPINAL CORD DISEASE; STROKE; THROMBOSIS; TONIC CLONIC SEIZURE; VISUAL HALLUCINATION; ANIMAL; CHEMICALLY INDUCED DISORDER; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN DISEASES; HUMANS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; SPINAL CORD DISEASES;

EID: 77954150370     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0030-1255217     Document Type: Review

References (177)

1. Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990 50 (19) 6203-6207
2. Wyllie A R., Bayliff C D., Kovacs M J. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 1997 31 (2) 171-174
3. Dropcho E J., Rosenfeld S S., Vitek J, Guthrie B L., Morawetz R B. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 1998 36 (2) 191-198
4. Baker W J., Royer G L. Jr, Weiss R B. Cytarabine and neurologic toxicity. J Clin Oncol 1991 9 (4) 679-693
5. Jaeckle K A., Batchelor T, O'Day S J. et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002 57 (3) 231-239
6. Jabbour E, O'Brien S, Kantarjian H et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007 109 (8) 3214-3218
7. Leff R S., Thompson J M., Daly M B. et al. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 1988 62 (1) 32-35
8. Pratt C B., Green A A., Horowitz M E. et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986 4 (8) 1253-1261
9. Pratt C B., Goren M P., Meyer W H., Singh B, Dodge R K. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990 8 (8) 1399-1401
10. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prov A, Vermorken J B. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000 82 (2) 291-294
11. Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004 15 (4) 347-350
12. Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 2007 19 108-114
13. DiMaggio J R., Brown R, Baile W F., Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994 73 (5) 1509-1514
14. Simonian N A., Gilliam F G., Chiappa K H. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology 1993 43 (12) 2700-2702
15. Buesa J M., Garca-Teijido P, Losa R, Fra J. Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res 2003 9 (12) 4636-4637
16. Pavol M A., Meyers C A., Rexer J L., Valentine A D., Mattis P J., Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995 45 (5) 947-950
17. Valentine A D., Meyers C A., Kling M A., Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998 25 (1, Suppl 1) 39-47
18. Hensley M L., Peterson B, Silver R T., Larson R A., Schiffer C A., Szatrowski T P. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000 18 (6) 1301-1308
19. Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988 6 (4) 355-359
20. Meyers C A., Scheibel R S., Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991 41 (5) 672-676
21. Musselman D L., Lawson D H., Gumnick J F. et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001 344 (13) 961-966
22. Denicoff K D., Rubinow D R., Papa M Z. et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987 107 (3) 293-300
23. Karp B I., Yang J C., Khorsand M, Wood R, Merigan T C. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology 1996 47 (2) 417-424
24. Baz D V., Bofill J S., Nogueira J A. Irinotecan-induced dysarthria. J Natl Cancer Inst 2001 93 (18) 1419-1420
25. Nieto Y, Cagnoni P J., Bearman S I. et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999 5 (3) 501-506
26. Perry J R., Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 1996 46 (6) 1596-1599
27. Ziske C G., Schttker B, Gorschlter M et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 2002 13 (4) 629-631
28. Rook J, Rosser T, Fangusaro J, Finlay J. Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatr Blood Cancer 2008 50 (3) 699-700
29. Byrd R L., Rohrbaugh T M., Raney R B. Jr, Norris D G. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 1981 47 (1) 37-40
30. Hurwitz R L., Mahoney D H. Jr, Armstrong D L., Browder T M. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988 16 (3) 216-219
31. Jansen C E., Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005 104 (10) 2222-2233
32. Kayl A E., Wefel J S., Meyers C A. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther 2006 13 (4) 362-369
33. Vardy J, Rourke S, Tannock I F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007 25 (17) 2455-2463
34. Wefel J S., Lenzi R, Theriault R, Buzdar A U., Cruickshank S, Meyers C A. Chemobrain in breast carcinoma? A prologue. Cancer 2004 101 (3) 466-475
35. Hermelink K, Untch M, Lux M P. et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007 109 (9) 1905-1913 (Pubitemid 46668557)
36. Inagaki M, Yoshikawa E, Matsuoka Y et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007 109 (1) 146-156
37. Silverman D H., Dy C J., Castellon S A. et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007 103 (3) 303-311
38. Ahles T A., Saykin A J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007 7 (3) 192-201
39. Rosenblum M K., Delattre J Y., Walker R W., Shapiro W R. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 1989 7 (3) 269-281
40. Hook C C., Kimmel D W., Kvols L K. et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992 31 (3) 262-267
41. Savarese D M., Gordon J, Smith T W. et al. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosisa case report. Cancer 1996 77 (2) 387-394
42. Franco D A., Greenberg H S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology 2001 56 (1) 110-112
43. Takimoto C H., Lu Z H., Zhang R et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996 2 (3) 477-481
44. Videnovic A, Semenov I, Chua-Adajar R et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005 65 (11) 1792-1794 discussion 1685
45. Robain O, Dulac O, Dommergues J P. et al. Necrotising leukoencephalopathy complicating treatment of childhood leukaemia. J Neurol Neurosurg Psychiatry 1984 47 (1) 65-72
46. Correa D D., DeAngelis L M., Shi W, Thaler H, Glass A, Abrey L E. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004 62 (4) 548-555
47. Harder H, Holtel H, Bromberg J E. et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004 62 (4) 544-547
48. Herrlinger U, Kker W, Uhl M et al, Neuro-Oncology Working Group of the German Society. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005 57 (6) 843-847 (Pubitemid 40798622)
49. Kingma A, van Dommelen R I., Mooyaart E L. et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 2001 139 413-420
50. Montour-Proulx I, Kuehn S M., Keene D L. et al. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 2005 20 (2) 129-133
51. Reddick W E., Glass J O., Helton K J., Langston J W., Li C S., Pui C H. A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. AJNR Am J Neuroradiol 2005 26 (9) 2371-2377
52. Omuro A M., Ben-Porat L S., Panageas K S. et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005 62 (10) 1595-1600
53. Oka M, Terae S, Kobayashi R et al. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 2003 45 (7) 493-497
54. Rubinstein L J., Herman M M., Long T F., Wilbur J R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975 35 (2) 291-305
55. Lai R, Abrey L E., Rosenblum M K., DeAngelis L M. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004 62 (3) 451-456
56. Linnebank M, Moskau S, Jrgens A et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro-oncol 2009 11 (1) 2-8
57. Chun H G., Leyland-Jones B R., Caryk S M., Hoth D F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986 70 (10) 1225-1228
58. Cheson B D., Vena D A., Foss F M., Sorensen J M. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994 12 (10) 2216-2228
59. Cohen R B., Abdallah J M., Gray J R., Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 1993 118 (2) 114-116
60. Feinberg W M., Swenson M R. Cerebrovascular complications of L-asparaginase therapy. Neurology 1988 38 (1) 127-133
61. Mitchell L G., Andrew M, Hanna K et al, Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003 97 (2) 508-516
62. Scappaticci F A., Skillings J R., Holden S N. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007 99 (16) 1232-1239
63. Zangari M, Fink L M., Elice F, Zhan F, Adcock D M., Tricot G J. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009 27 (29) 4865-4873
64. Norden A D., Young G S., Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008 70 (10) 779-787
65. Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009 110 (1) 173-180
66. Friedman H S., Prados M D., Wen P Y. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009 27 (28) 4733-4740
67. Nghiemphu P L., Green R M., Pope W B., Lai A, Cloughesy T F. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-oncol 2008 10 (3) 355-360
68. Carden C P., Larkin J M., Rosenthal M A. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro-oncol 2008 10 (4) 624-630
69. El Amrani M, Heinzlef O, Debroucker T, Roullet E, Bousser M G., Amarenco P. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology 1998 51 (3) 899-901
70. Serrano-Castro P J., Guardado-Santervs P, Olivares-Romero J. Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study. Eur Neurol 2000 44 (1) 63-64
71. Russmann S, Winkler A, Lvblad K O., Stanga Z, Bassetti C. Lethal ischemic stroke after cisplatin-based chemotherapy for testicular carcinoma and cannabis inhalation. Eur Neurol 2002 48 (3) 178-180
72. Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 2004 38 (2) 242-246
73. Bernard J T., Ameriso S, Kempf R A., Rosen P, Mitchell M S., Fisher M. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990 40 (1) 154-155
74. Walker R W., Allen J C., Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986 4 (12) 1845-1850
75. Rubnitz J E., Relling M V., Harrison P L. et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998 12 (8) 1176-1181
76. Eichler A F., Batchelor T T., Henson J W. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro-oncol 2007 9 (3) 373-377
77. Inaba H, Khan R B., Laningham F H., Crews K R., Pui C H., Daw N C. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008 19 (1) 178-184
78. Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 2004 25 (10) 1688-1695
79. Fisher M J., Khademian Z P., Simon E M., Zimmerman R A., Bilaniuk L T. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 2005 26 (7) 1686-1689
80. Haykin M E., Gorman M, van Hoff J, Fulbright R K., Baehring J M. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006 76 153-157
81. Balin J, Parmar H, Kujawski L. Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity. J Neurol Sci 2008 269 (1-2) 169-171
82. Drachtman R A., Cole P D., Golden C B. et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002 19 (5) 319-327
83. Jaksic W, Veljkovic D, Pozza C, Lewis I. Methotrexate-induced leukoencephalopathy reversed by aminophylline and high-dose folinic acid. Acta Haematol 2004 111 (4) 230-232
84. Ay H, Buonanno F S., Schaefer P W. et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998 51 (5) 1369-1376
85. Tam C S., Galanos J, Seymour J F., Pitman A G., Stark R J., Prince H M. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004 77 (1) 72-76
86. Snchez-Carpintero R, Narbona J, Lpez de Mesa R, Arbizu J, Sierrasesmaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001 24 (2) 145-148
87. Suminoe A, Matsuzaki A, Kira R et al. Reversible posterior leukoencephalopathy syndrome in children with cancers. J Pediatr Hematol Oncol 2003 25 (3) 236-239
88. Morris E B., Laningham F H., Sandlund J T., Khan R B. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer 2007 48 (2) 152-159
89. Shin R K., Stern J W., Janss A J., Hunter J V., Liu G T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology 2001 56 (3) 388-391
90. Allen J A., Adlakha A, Bergethon P R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006 63 (10) 1475-1478
91. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006 354 (9) 980-982 discussion 980-982
92. Henderson R D., Rajah T, Nicol A J., Read S J. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology 2003 60 (2) 326-328
93. Covarrubias D J., Luetmer P H., Campeau N G. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 2002 23 (6) 1038-1048
94. Smith G A., Damon L E., Rugo H S., Ries C A., Linker C A. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997 15 (2) 833-839
95. Winkelman M D., Hines J D. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983 14 (5) 520-527
96. Pirzada N A., Ali I I., Dafer R M. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000 34 (1) 35-38
97. Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol 1997 34 (2) 163-167
98. Anderson N R., Tandon D S. Ifosfamide extrapyramidal neurotoxicity. Cancer 1991 68 (1) 72-75
99. Resar L M., Phillips P C., Kastan M B., Leventhal B G., Bowman P W., Civin C I. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993 71 (1) 117-123
100. Raney B, Tefft M, Heyn R et al. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer 1992 69 (6) 1498-1506
101. McLean D R., Clink H M., Ernst P et al. Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes. Cancer 1994 73 (12) 3037-3040
102. Kleinschmidt-DeMasters B K., Yeh M. Locked-in syndrome after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 1992 70 (10) 2504-2507
103. Richardson P G., Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006 24 (19) 3113-3120
104. Badros A, Goloubeva O, Dalal J S. et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007 110 (5) 1042-1049
105. Argyriou A A., Iconomou G, Kalofonos H P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008 112 (5) 1593-1599
106. San Miguel J F., Schlag R, Khuageva N K. et al, VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 359 (9) 906-917
107. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990 66 (6) 1117-1123
108. Cavaletti G, Marzorati L, Bogliun G et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992 69 (1) 203-207
109. Ta L E., Espeset L, Podratz J, Windebank A J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006 27 (6) 992-1002
110. McWhinney S R., Goldberg R M., McLeod H L. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009 8 (1) 10-16
111. Dzagnidze A, Katsarava Z, Makhalova J et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007 27 (35) 9451-9457
112. Boogerd W, ten Bokkel Huinink W W., Dalesio O, Hoppenbrouwers W J., van der Sande J J. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990 9 (3) 255-263
113. Strumberg D, Brgge S, Korn M W. et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002 13 (2) 229-236
114. Heinzlef O, Lotz J P., Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998 64 (5) 667-669
115. Openshaw H, Slatkin N E., Stein A S., Hinton D R., Forman S J. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 1996 78 (9) 1899-1905
116. Lee J J., Low J A., Croarkin E et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 2006 24 (13) 2084-2091
117. Imrie K R., Couture F, Turner C C., Sutcliffe S B., Keating A. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant 1994 13 (1) 77-79
118. Stein M E., Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol 1998 21 (3) 248-249
119. Saif M W., Wilson R H., Harold N, Keith B, Dougherty D S., Grem J L. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 2001 12 (6) 525-531
120. Saif M W., Wood T E., McGee P J., Diasio R B. Peripheral neuropathy associated with capecitabine. Anticancer Drugs 2004 15 (8) 767-771
121. Frisk P, Stlberg E, Strmberg B, Jakobson A. Painful peripheral neuropathy after treatment with high-dose ifosfamide. Med Pediatr Oncol 2001 37 (4) 379-382
122. Patel S R., Forman A D., Benjamin R S. High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 1994 86 (4) 305-306
123. Koh S, Nelson M D. Jr, Kovanlikaya A, Chen L S. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999 21 (2) 576-578
124. Bay A, Oner A F., Etlik O, Yilmaz C, Caksen H. Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 2005 27 (5) 270-272
125. Pascual A M., Coret F, Casanova B, Linez M J. Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate. J Neurol Sci 2008 267 (1-2) 158-161
126. Argyriou A A., Polychronopoulos P, Iconomou G, Chroni E, Kalofonos H P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008 34 (4) 368-377
127. Wilson R H., Lehky T, Thomas R R., Quinn M G., Floeter M K., Grem J L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002 20 (7) 1767-1774
128. Lehky T J., Leonard G D., Wilson R H., Grem J L., Floeter M K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004 29 (3) 387-392
129. Webster R G., Brain K L., Wilson R H., Grem J L., Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005 146 (7) 1027-1039
130. Krishnan A V., Goldstein D, Friedlander M, Kiernan M C. Oxaliplatin and axonal Na+channel function in vivo. Clin Cancer Res 2006 12 (15) 4481-4484
131. Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002 94 (9) 2434-2440
132. Krishnan A V., Goldstein D, Friedlander M, Kiernan M C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005 32 (1) 51-60
133. Park S B., Lin C S., Krishnan A V., Goldstein D, Friedlander M L., Kiernan M C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009 132 (Pt 10) 2712-2723
134. Land S R., Kopec J A., Cecchini R S. et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007 25 (16) 2205-2211
135. Durand J P., Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005 16 (5) 587-591
136. Argyriou A A., Chroni E, Polychronopoulos P et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006 67 (12) 2253-2255
137. Gamelin L, Boisdron-Celle M, Delva R et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004 10 (12 Pt 1) 4055-4061
138. Gamelin L, Capitain O, Morel A et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007 13 (21) 6359-6368
139. Chaudhry V, Eisenberger M A., Sinibaldi V J., Sheikh K, Griffin J W., Cornblath D R. A prospective study of suramin-induced peripheral neuropathy. Brain 1996 119 (Pt 6) 2039-2052
140. Soliven B, Dhand U K., Kobayashi K et al. Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 1997 20 (1) 83-91
141. Cavaletti G, Bogliun G, Marzorati L et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995 75 (5) 1141-1150
142. Forsyth P A., Balmaceda C, Peterson K, Seidman A D., Brasher P, DeAngelis L M. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997 35 (1) 47-53
143. Hilkens P H., Verweij J, Stoter G, Vecht C J., van Putten W L., van den Bent M J. Peripheral neurotoxicity induced by docetaxel. Neurology 1996 46 (1) 104-108
144. New P Z., Jackson C E., Rinaldi D, Burris H, Barohn R J. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996 46 (1) 108-111
145. Persohn E, Canta A, Schoepfer S et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005 41 (10) 1460-1466
146. Lee J J., Swain S M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006 24 (10) 1633-1642
147. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006 42 (1) 24-30
148. van den Bent M J., Hilkens P H., Sillevis Smitt P A., van Raaij-van den Aarssen V J., Bontenbal M, Verweij J. Lhermitte's sign following chemotherapy with docetaxel. Neurology 1998 50 (2) 563-564
149. Chaudhry V, Rowinsky E K., Sartorius S E., Donehower R C., Cornblath D R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994 35 (3) 304-311
150. Freilich R J., Balmaceda C, Seidman A D., Rubin M, DeAngelis L M. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996 47 (1) 115-118
151. Chaudhry V, Chaudhry M, Crawford T O., Simmons-O'Brien E, Griffin J W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003 60 (2) 337-340
152. Berger T, Malayeri R, Doppelbauer A et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997 33 (9) 1393-1399
153. Cavaletti G, Beronio A, Reni L et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004 62 (12) 2291-2293
154. Molloy F M., Floeter M K., Syed N A. et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001 24 (8) 1050-1057
155. Chaudhry V, Cornblath D R., Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002 59 (12) 1872-1875
156. Tosi P, Zamagni E, Cellini C et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005 74 (3) 212-216
157. Offidani M, Corvatta L, Marconi M et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004 72 (6) 403-409
158. Mileshkin L, Stark R, Day B, Seymour J F., Zeldis J B., Prince H M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006 24 (27) 4507-4514
159. Plasmati R, Pastorelli F, Cavo M et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007 69 (6) 573-581
160. Casey E B., Jellife A M., Le Quesne P M., Millett Y L. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973 96 (1) 69-86
161. Verstappen C C., Koeppen S, Heimans J J. et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005 64 (6) 1076-1077
162. Graf W D., Chance P F., Lensch M W., Eng L J., Lipe H P., Bird T D. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996 77 (7) 1356-1362
163. Hildebrandt G, Holler E, Woenkhaus M et al. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 2000 11 (6) 743-747
164. Kalfakis N, Panas M, Karadima G, Floroskufi P, Kokolakis N, Vassilopoulos D. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002 59 (9) 1470-1471
165. Weintraub M, Adde M A., Venzon D J. et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996 14 (3) 935-940
166. Pace A, Bove L, Nistic C et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996 61 (4) 409-411
167. Apfel S C. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest 2000 18 (6) 564-573
168. Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 2002 38 (14) 1832-1837
169. Leong S S., Tan E H., Fong K W. et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003 21 (9) 1767-1774
170. Lorusso D, Ferrandina G, Greggi S et al, Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003 14 (7) 1086-1093
171. Openshaw H, Beamon K, Synold T W. et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004 10 (2) 461-467
172. De Vos F Y., Bos A M., Schaapveld M et al. A randomized phase II study of paclitaxel with carboplatin+/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 2005 97 (1) 60-67
173. Hensley M L., Hagerty K L., Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009 27 (1) 127-145
174. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002 20 (16) 3478-3483
175. Argyriou A A., Chroni E, Koutras A et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005 64 (1) 26-31 (Pubitemid 40082932)
176. Bianchi G, Vitali G, Caraceni A et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005 41 (12) 1746-1750
177. Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crin L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005 91 (2) 135-138